Advertisement

Symptomkontrolle

  • Herbert Watzke
Chapter
  • 3.8k Downloads

Zusammenfassung

Oft leiden Palliativpatienten mehr unter belastenden Symptomen als unter Schmerzen. Atemnot ist zuerst ein subjektives Gefühl, dessen Schwere nur Patienten selbst beurteilen können. Eine sorgfältige Ursachensuche ist angezeigt. Übelkeit und Erbrechen können ebenso verschiedene Gründe haben, sei es im Verdauungstrakt, Stoffwechselentgleisungen, im Gehirn oder als Medikamentennebenwirkung. Ein häufiges Problem stellt die Obstipation dar, wozu individuell angepasste und richtlinientreue Behandlungskonzepte dargestellt werden. Intestinale Obstruktion und Hyperkalzämie können zu schwerer Symptomlast führen, die differenziert anzugehen ist. Sehr belastend für Patienten, Angehörige und die Pflege ist ein terminales Delir, das ebenfalls sehr häufig auftritt.

Literatur

  1. Adams L, Chronos N, Lane G, Guz A (1985) The measurement of breathlessness induced in normal subjects: validity of two scaling techniques. Clin Sci (Lond) 69:7–16Google Scholar
  2. Akechi T, UchitomiY, Okumura H (1996) Usage of haloperidol for delirium in cancer patients. Support Cancer Care 4:390–392Google Scholar
  3. Allard P, Lamontagne C, Bernard P, Trenblay C (1999) How effective are supplementary doses of opioids for dyspnea in terminally ill cancer patients. J Pain Symptom Manage 17:256–265Google Scholar
  4. Alt-Epping B, Sitte T, Nauck F, Radbruch L (2010) Sedierung in der Palliativmedizin. Z Palliativmed 11:112–122Google Scholar
  5. American Psychiatric Association (1994) Diagnostic and statistical Manual of Mental disorders. APA, Washington DCGoogle Scholar
  6. Anti M, Pignataro G, Armuzzi A et al (1998) Water supplementation enhances the effect of high fiber diet on stool frequency and laxative consumption in adult patients with functional constipation. Hepatogastroenterology 45:727Google Scholar
  7. AWMF (2013) S2k-Leitlinie Chronische Obstipation, aktueller Stand: 02/2013. Register-Nr. 021/019Google Scholar
  8. AWMF (2015) S3-Leitlinie Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung, Version 1.0 – Mai 2015. Register-Nr: 128/001OLGoogle Scholar
  9. Bausewein C, Booth S, Gysels M, Kühnbach R, Higginson IJ (2010) Effectiveness of a hand-held fan for breathlessness: a randomised phase II trial. BMC Palliat Care doi:  10.1186/1472-684X-9-22
  10. Body JJ, Bartl R, Bruckhardt P et al (1998) Current use of bisphosphonates in oncology. J Clin Oncol 16(12):3890–3899Google Scholar
  11. Borg GA (1982) Psychophysical bases of perceived exertion. Med Sci Sports Exerc 14:377–781Google Scholar
  12. Breitbart W, Marotty R, Platt M (1996) A double-blind comparison trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 153:231–237Google Scholar
  13. Breitbart W (2001) Diagnosis and management of delirium in the terminally ill. In: Portenoy, Bruera E, (eds) Topics in Palliative care, Vol5. Oxford University Press, New York, pp 303–321Google Scholar
  14. Bruera E, Fainsinger R, Miller M, Kuehn N (1992) The assessment of pain intensity in patients with cognitive failure J Pain Symp Man 7(5):267–270Google Scholar
  15. Bruera E, Hui D, Dalal S, Torres-Vigil I et al (2013) Parenteral hydration in patients with advanced cancer: a multicenter, double-blind, placebo-controlled randomized trial. J Clin Oncol 31(1):111–118Google Scholar
  16. Chua TP, Harrington D, Ponikowski P et al (1997) Effects of dihydrocodein on chemosensitivity and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 29:147–152Google Scholar
  17. Currow DC, Coughlan M, Fardell B, Cooney NJ (1997) Use of ondasentron in palliative medicine. J Pain Symptom Manage 13:302–307Google Scholar
  18. Currow DC, Quinn S, Agar M et al (2015) Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction. J Pain Symptom Manage 49(5):814–821Google Scholar
  19. Davis K, Attie M (1991) Management of severe hypercalcaemia. Crit Care Clin 7:175–190Google Scholar
  20. Drossman DA (2006) Rome III: The Functional Gastrointestinal Disorders, 3rd ed. Degnon Associates Inc, McLean, VAGoogle Scholar
  21. Drossman et al (1990) Identificationof subgroups of functiomal gastrointestinal disorders. Gatroenterol Int 3:159–172Google Scholar
  22. Emanuel EJ, Fairclough DL, Slutsman J, Emanuel LL (2000) Understanding economic and other burdens of terminal illness: experience of patients and their caregivers. Ann Intern Med 132:451–459Google Scholar
  23. Evans KC, Bahnzett RB, Adams L (2002) BOLD fMRI identifies limbic, paralimbic, and cerebellar activation during air hunger. J Neurophysiol 88:1500–1511Google Scholar
  24. Fainsinger R, McEachern T, Hanson J (1991) Symptome control during the last week of life in a palliative care unit. J Palliative Care 7:5–11Google Scholar
  25. Fallon B (1998) Nausea and vomiting unrelated to case treatment. In: Berger AM, Portenoy RK, Weissman DE (eds) Principle and Practice of Supportive Oncology. Lippincott Williams and Wilkins, Philadelphia, pp 179–190Google Scholar
  26. Fernandez F, Levy J, Mansell P (1989) Management of delirium in terminally ill AIDS patients. Int J Psychiat Med 19:165–172Google Scholar
  27. Feuer DJ, Broadley (1999) Systematic review of corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancers. Ann Oncol 10:1035–1040Google Scholar
  28. Gaginella TS, Bris P (1978) Laxatives: an update on the mechanism of action. Life Sci 23:1001–1010Google Scholar
  29. George J, Crawford D, Lewis T et al (1990) Percutaneous endoscopic gastrostomy: a tow year experience. Med J Aust 152:17–20Google Scholar
  30. Glare P, Peirera G, Krsitjanson LJ et al (2001) Systematic review of the efficacy of antiemetic in the treatment of nausea in patients with far-advanced cancer. Support Care Cancer 12:432–440Google Scholar
  31. Gonzales-Rosales F, Walsh D (1997) Intractable nausea and vomiting due to gastrointestinal mucosal metastases relieved by tetrahydrocannabinol. 14(5):311–314Google Scholar
  32. Hardy J, Daly S, McQuade B et al (2002) A double-blind, randomized parallel group, multinational, multi-centre study comparing ondansetron 24 mg p.o. with placebo and metoclopramide 10 mf tds p.o. in the treatment of opioid induced nausea and emesis in cancer patients. Support Care Cancer 10:331–336Google Scholar
  33. Heath DA (1989) Hypercalcemia of malignancy. BMJ 298:1468–1469Google Scholar
  34. Hestermann U, Backenstrass M, Gekle I et al (2009) Validation of a German version of the Confusion Assessment Method for delirium detection in a sample of acute geriatric patients with a high prevalence of dementia. Psychopathology 42(4):270–276Google Scholar
  35. Higgins I McCarthyM (1989) Measuring Symptoms in terminal cancer: are pain and dyspnea controlled? J R Soc Med 82:264–266Google Scholar
  36. Holmes S (1989) Use of a modified symptom distress scale in assessment of the cancer patient. Int J Nurs Stud 26:69–7932Google Scholar
  37. Inouye B, Bogardus Jr S, Charpentier P et al (1999) A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med 340(9):669–676Google Scholar
  38. Johnson MJ, MC Donagh TA, Harkness A, et al (2001) Morphine for the relief of breathlessness in patients with chronic heart failure-a pilot study. Eur J Heart Fail 4:753–756Google Scholar
  39. Kovacs C, MacDonald S, Chik C, Bruera E (1995) Hypercalcemia of malignancy in the palliative care patient: a treatment strategy. J Pain Symptom Manage 10:224–232Google Scholar
  40. Lawlor P, Gagnon B, Mancini I et al (2001) The occurrence, causes and outcome of delirium in advanced cancer patients: a prospective study. Arch Int Med 160:786–794Google Scholar
  41. Leupoldt A, Dahme B (2005) Cortical substrates for the perception of dyspnea. Chest 128(1):345–354Google Scholar
  42. Light RW, Muro JR, Sato RI, et al (1989) Effects of oral morphine on breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 139:126–133Google Scholar
  43. Lowler P (2002) Delirium and dehydration: Some fluid for thought? Support Care Cancer 195:835–839Google Scholar
  44. MacKintosh D (2016) Olanzapine in the Management of Difficult to Control Nausea and Vomiting in a Palliative Care Population: A Case Series. J Palliat Med 19:87–90Google Scholar
  45. Major P (2001) Use of zeolendroic acid, a novel, highly potent bisphosphonate, for treatment of hypercalcemia of malignancy. Oncologist 7:481–491Google Scholar
  46. Manning HL, Schwartzstein RM (1995) Pathophysiology of dyspnea. N Engl J Med 333:1547–1553Google Scholar
  47. Massie M, Holland J, Glass E (1983) Delirium in terminally ill cancer patients. Am J Psychiatry 140:1048–1050Google Scholar
  48. Mazzocatto C, Buclin T, Rapin CH (1999) The effects of morphine on dyspnea on ventilator function in elderly patients with advanced cancer: a randomized double-blind controlled trial. Annal Oncol 10:1511–1014Google Scholar
  49. Menza M, Murray G, Holmes V (1988) Controlled study of extrapyramidal reactions in the management of delirious medically ill patients: Intravenous Haldol versus Haldol plus benzodiazepines. Heart Lung 17:2318–2341Google Scholar
  50. Mercadante S, Avola G, Maddaloni S et al (1996) Octreotide prevents the pathological alterations of bowl obstruction in cancer patients. Support Care Cancer 4:393–394Google Scholar
  51. Mercadante S, DE Conno F, Ripamonti C (1995) Propofol in terminal care. J Pain Symptom Manage 10:639–642Google Scholar
  52. Mercadante S, Spoldi, Caraceni A et al (1993) Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliat Med 7:295–299Google Scholar
  53. Morita T, Hyodo I, Yoshimi T et al (2004) Incidence and underlying etiologies of bronchial secretion in terminally ill cancer patients: a multicenter, prospective, observational study. J Pain symptom Manage 27:533–539Google Scholar
  54. Morita T, Tsunoda J, Inoue S et al (1999) Perception and decision-making on rehydration of terminally ill cancer patients and family members. Am J Hosp Palliat Care 16:509–516Google Scholar
  55. Moyle J (1995) The use of propofol in palliative medicine. J Pain Symptom Manage10:643–646Google Scholar
  56. Muers MF, Round CE (1993) Palliation of symptoms in non-small cell lung cancer: a study by the Yorkshire Regional Cancer Organization Thoracic Group. Thorax 48:339–343Google Scholar
  57. Nash Smyth E, Conti I, Wooldridge JE et al (2015) Frequency of skeletal-related events and associated health care resource use and costs in US patients with multiple myeloma. J Med Econ 15:1–26Google Scholar
  58. Nellgard P, Bojo L, Cassuto J (1995) Importance of vasoactive intestinal peptide and somatostatin for fluid loss in small bowl obstruction. Scand J Gastroenterol 30:464–469Google Scholar
  59. Nelville R, Fielding P, Cambria RP, Modlin I (1991) Vascular responsiveness in obstructive gut. Dis Colon Rectum 4:229–235Google Scholar
  60. Oliver D (1985) The use of methotrimeprazine in terminal care. BrJ Clin Pract 39:339–340Google Scholar
  61. Passik S, Cooper M (1999) Complicated delirium in cancer patients successfully treated with olanzapine. J Pain Symptom Manage 7:219–223Google Scholar
  62. Patel S, Lyons A, Hosking D (1993) Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use. Drugs 46:594–617Google Scholar
  63. Pictus D, Marx MV, Weyman PJ (1988) Chronic intestinal obstruction: value of percutaneous gastrostomy tube placement. Am J Radiol 150:295–297Google Scholar
  64. Reuben DB, Mor V (1986) Dyspnea in terminally ill cancer patients. Chest 89:234–326Google Scholar
  65. Reynolds JC, Putnam PE (1992) Prokinetic agents. Gastroenterol Clin North Am 21:567–596Google Scholar
  66. Ripamonti C, Panzeri C, Groff L et al (2001) The role of somatostatin and octreotide in bowl obstruction: pre-clinical and clinical results. Tumori 87:1–9Google Scholar
  67. Sarhill N, Walsh D, Nelson K, Davis M (2001) Evaluation and treatment of cancer related fluid deficits: volume depletion or dehydration. Support Care Cancer 9:408–419Google Scholar
  68. Schwartz T, Massand P (2001) The role of atypical antipsychotics in the treatment of delirium. Psychosomatics 43:171Google Scholar
  69. Sipahimalami A, Sime RM ,Massand P (1997) Treatment of delirium with risperdon. In J Geriatric Psychopharmacol 1:24–26Google Scholar
  70. Srivastava M, Brito-Dellan N, Davis MP et al (2003) Olanzapine a s an antiemetic in refractory nausea and vomiting in advanced cancer. J Palliat Med 6:251–255Google Scholar
  71. Stark RD, Gambles SA, Lewis JA (1981) Methods to access breathlessness in healthy subjects: a critical evaluation and application to analyze the acute effects of diazepam and promethazin on breathlessness induced by exercise or by exposure to raised levels of carbon dioxide. Clin Sci (Lond) 61:429–439Google Scholar
  72. Stiefel F, Kornblith A, Holland J, Coyle N, Breitbart W, Weaver S, Portenoy R (1994) Delirium as a contributing factor to ›crescendo pain: Three case reports. J Pain Symptom Manage; 9:44–47Google Scholar
  73. Thomas JR, von Guten CH (2006) Dyspnea. In: Bruera E, Higgins IJ, Ripamonti C, von Guten CH (eds) Textbook of Palliative Medicine. Oxford University Press 655–662Google Scholar
  74. Twycross R, Back I (1998) Nausea and vomiting in advanced cancer. Eur J Palliat Care 5:39–45Google Scholar
  75. Ventafridda V, Ripamonti C, Caraceni A et al (1990) The management of inoperable gastrointestinal obstruction in terminal cancer patients. Tumori 76:389–393Google Scholar
  76. Ventafridda V, Ripamonti C, DeConno F (1990) Symptom prevalence and control during cancer patients´ last days of life. J Palliat Care 6:7–11Google Scholar
  77. Wald A (2000) Constipation. Med Clin North Am 84:1231Google Scholar
  78. Williams SG, Wright DJ, Marshall P et al (2002) Safety and potential benefits of low dose diamorphine during exercise in patients with chronic heart failure. Heart 88:1085–1086Google Scholar
  79. Woodcock AA, Gross ER, Geddes DM (1981) Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. Br Med J (Clin Re Ed) 281:343–346Google Scholar
  80. Zebraski SE, Kochenash SM, Raffa RB (2000) Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Lif Sci 66:2221–2231Google Scholar

Copyright information

© Springer-Verlag GmbH Deutschland 2017

Authors and Affiliations

  • Herbert Watzke
    • 1
  1. 1.Leiter der Klinischen Abteilung für PalliativmedizinMedizinische Universität Wien Allgemeines Krankenhaus WienWienÖsterreich

Personalised recommendations